글로벌 항결핵 치료제 시장 – 2029년까지의 산업 동향 및 예측

시장 분석 및 규모

최근 몇 년 동안 항결핵 치료제 시장은 예측 기간 동안 빠르게 성장할 것으로 예상됩니다. WHO의 2020년 세계 결핵(TB) 보고서에 따르면 약 150만 명이 결핵(TB)으로 사망했습니다. 결핵은 전 세계적으로 10대 사망 원인 중 하나이며 단일 감염원으로 인한 사망의 주요 원인입니다. 전반적으로 결핵과 다중 약물 내성 결핵의 전 세계적 발생률은 주요 의료 규제 기관에 과제를 안겨줍니다. 의료계와 정부가 결핵과 싸우는 데 크게 관여함에 따라 결핵 진단 건수가 증가할 것으로 예상됩니다. 따라서 항결핵 치료제 시장에 대한 수요가 높아졌습니다.

Data Bridge Market Research는 항결핵 치료제 시장이 2021년에 12억 6,627만 달러 규모였으며 2029년까지 21억 2,736만 달러에 도달할 것으로 예상되며 2022년에서 2029년까지의 예측 기간 동안 6.70%의 CAGR을 기록할 것으로 분석했습니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함되어 있습니다.

시장 정의

결핵(TB)은 일반적으로 폐를 감염시키는 전염성 감염입니다. 이 질병은 척추와 뇌와 같은 다른 신체 부위로 퍼질 수도 있습니다. 결핵균은 이를 유발하는 박테리아의 한 형태입니다. 제약 회사는 치료 기간을 단축하고 약물에 취약하고 약물에 내성이 있는 결핵의 장애물을 극복하는 데 도움이 되는 약물을 만드는 데 노력을 집중하고 있습니다. 결핵 치료에는 1차 치료, 2차 치료 및 약물 내성 치료의 두 가지 형태가 있습니다.

보고 범위 및 시장 세분화

항결핵 치료제 시장 동향

운전자

• 결핵 유병률 증가

결핵 유병률 증가는 항결핵 치료제 시장 성장률을 견인하는 주요 요인입니다. 2020년에 전 세계적으로 약 1,000만 명이 결핵에 걸렸습니다. 그 중 330만 명이 여성이었고, 560만 명이 남성이었고, 110만 명이 어린이였습니다. 결핵(TB)은 공기를 통해 사람 간에 전파됩니다. 폐결핵 환자는 기침, 재채기 또는 침을 뱉을 때 공기 중으로 TB 세균을 퍼뜨립니다. 사람은 이러한 세균을 몇 개만 흡입해도 감염됩니다.

• 의료 인프라에 대한 투자 증가

항결핵 치료제 시장의 성장률에 영향을 미치는 또 다른 중요한 요인은 인프라를 개선하는 데 도움이 되는 의료비 지출 증가입니다. 또한, 다양한 정부 기관은 자금을 늘려 의료 인프라를 개선하고자 하며, 이는 시장 역학에 더욱 영향을 미칠 것입니다.

• 노령 인구의 증가

The rising geriatric population is expected to enhance the growth rate of anti-tuberculosis therapeutics market. Geriatric people are more prone to chronic and acute diseases due to the weak immune system. Various conditions such as diabetes, HIVAIDS, kidney diseases and others are the major factors that will weak the immune system. Along with this, certain medication, including chemotherapy, drugs used to treat Crohn's disease, rheumatoid arthritis, and psoriasis, will increase the risk of tuberculosis as these can weaken the immune system.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the anti-tuberculosis therapeutics market. Additionally, changing lifestyle of people and rising incidences of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) cases in developing countries will result in the expansion of anti-tuberculosis therapeutics market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the anti-tuberculosis therapeutics market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. The advent of new and more efficient diabetic treatment and monitoring products is estimated to boost the market's growth rate in the future. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the anti-tuberculosis therapeutics market during the forecast period.

Restraints/Challenges

On the other hand, the high cost of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) drugs will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and product recalls will challenge the anti-tuberculosis therapeutics market. Additionally, side effects linked with anti-tuberculosis drugs will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This anti-tuberculosis therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the anti-tuberculosis therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Anti-tuberculosis therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Anti-Tuberculosis Therapeutics Market

Over the projected period, the anti-tuberculosis therapeutics market is expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations have imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world are having difficulty continuing their supply chain activities. The supply chain slowness has also hampered the anti-tuberculosis therapeutics market.

Global Anti-Tuberculosis Therapeutics Market Scope

The anti-tuberculosis therapeutics market is segmented on the basis of diseases type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Active TB
• Latent TB
• Others

Treatment Type

• First-Line of Drugs
  • Isoniazid
  • Ethambutol
  • Rifampin
  • Others
• Second-Line of Drugs
  • Thiacetazone
  • Paraaminosalicyclic Acid (PAS)
  • Others
• Others

Diagnosis

• Blood Tests
• Imaging Tests
  • Chest X-ray
  • CT scan
• Sputum Tests
• Others

Dosage form

• Tablets
• Capsules
• Injections
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Anti-Tuberculosis Therapeutics Market Regional Analysis/Insights

The anti-tuberculosis therapeutics market is analysed and market size insights and trends are provided by country, diseases type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Anti-tuberculosis therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the anti-tuberculosis therapeutics market because of the growing number of research and development activities and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, increasing adoption of Bacillus Calmette–Guérin (BCG) vaccine will further influence the market's growth rate in this region

Asia-Pacific are expected to grow during the forecast period due to surging number of generic manufacturers in this region. Also, development of healthcare infrastructure and increasing government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Anti-Tuberculosis Therapeutics Market Share Analysis

The Anti-tuberculosis therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to anti-tuberculosis therapeutics market.

Some of the major players operating in the anti-tuberculosis therapeutics market are:

• AstraZeneca (UK)
• Johnson & Johnson Private Limited (US)
• Eli Lilly and Company (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Novartis AG (Switzerland)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Allergan (Ireland)
• Merck & Co., Inc. (US)
• Pfizer Inc. (US)
• GlaxoSmithKline plc (영국) 
• 히크마 제약(영국)
• 시플라 주식회사(미국)
• 라넷(미국)
• Fresenius Kabi AG(독일)
• 엔도 인터내셔널 주식회사(아일랜드)
• 오츠카제약 주식회사(일본)
• STI Pharma, LLC(미국)
• Macleods Pharmaceuticals Ltd.(인도)

SKU-53710